期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

前列腺癌内分泌治疗进展 被引量：3

原文传递
导出
摘要 在欧美国家前列腺癌为发病率最高的恶性肿瘤,近年来国内前列腺癌发病率也明显呈上升趋势。内分泌治疗是当前采用的主要临床方法之一,其机制是抑制雄激素的活性。一线内分泌治疗后无效的前列腺癌是临床目前面临的一个棘手问题。现就前列腺癌内分泌治疗的机制、分类、用药策略及一线内分泌治疗后无效的前列腺癌治疗的进展做一综述。
作者 王理扬 姚文秀
机构地区 四川省肿瘤医院内二科
出处 《华西医学》 CAS 2011年第7期1112-1115,共4页 West China Medical Journal
关键词 前列腺肿瘤 受体 雄激素 药物疗法
分类号 R737.25 [医药卫生—肿瘤] R730.5 [医药卫生—肿瘤]
  • 相关文献

参考文献30

  • 1Jemal A, Siegel R, Xu J, etal. Cancer Statistics, 2010[J]. CA Cancer J Clin, 2010, 60(5):277-300.
  • 2Huggins C, Hodges CV. Studies on prostate cancer I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate[J]. Cancer Res, 1941, 1: 293-297.
  • 3Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix., a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer [J]. BJU Int, 2008, 102(11): 1531-1538.
  • 4黄海,许可慰,黄健,董文,江春,林天歆,郭正辉,姚友生,谢文练,韩金利.晚期前列腺癌内分泌治疗药物的疗效观察[J].中华泌尿外科杂志,2010,31(1):45-48. 被引量：16
  • 5Moul JW. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer [ J ]. Cancer, 2009, 115(15): 3376-3378.
  • 6Cruz Guerra NA. Outcomes from the use of maximal androgen blockade in prostate cancer at health area with reference hospital type 2 (1st part). Quality of life: application of EORTC QLQ- C30 instrument[J]. Arch Esp Urol, 2009, 62(6): 431-457.
  • 7Prayer-Galetti T, Sacco E, Pagano F, et al. Long-term follow- up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer[J]. BJU Int, 2007, 100(2): 274-280.
  • 8Shelley MD, Kumar S, Wilt T, et al. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma[J]. Cancer Treat Rev, 2009, 35(1): 9-17.
  • 9Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node- positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy[J]. Lancet Oncol, 2006, 7(6): 472-479.
  • 10Iversen P, Johansson JE, Lodding P, et al. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7. 1 years[J]. Scand J Urol Nephrol, 2006, 40(6): 441-452.

二级参考文献21

  • 1Marc BG. Hormonal therapy in the management of prostate cancer: from Huggins to the present. Urology, 1997,49 (suppl3A) : 5-8.
  • 2Geller J, Albert J. Comparison of prostatic cancer tissue dihydrotestoster one level sat the time of relaple following orchiectomyo restrogen therapy. J Urol, 1984, 132.. 693-696.
  • 3Laurence K, Koichiro A, David G, et al. Advanced prostate cancer: hormones and beyond. Eur Urol Suppl, 2007, 6: 354-364.
  • 4Cassileth BR, Soloway MS, Vogelzang NJ, et al. Quality of life and psychosocial status in stage D prostate cancer. Qual Life Res, 1992, 1: 323-330.
  • 5Smith MR, Fallon MA, Goode MJ. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology, 2003, 61.. 127-131.
  • 6Tyrrell CJ, Kaisary AV, Iversen P, et al. A randomized comparison of ' Casodex' 1 (biealutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol, 1998, 33: 447- 456.
  • 7Iversen P, Tyrrell CJ, Kaisary AV, et al. Bicalutamide monotherapy compared with castration in patients with non metastatic locally advanced prostate cancer: 6.3 years of followup. J Urol, 2000, 164: 1579-1582.
  • 8Tannoek IF, De Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med, 2004, 351: 1502-1512.
  • 9Miyake H, Hara I, Eto H. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refraetory prostate cancer. BJU Int, 2005, 96: 791-795.
  • 10Klotz L. Maximal androgen blockade for advanced prostate cancer. Best Pract Res Clin Endocrinol Metab, 2008, 22: 331-340.

共引文献30

同被引文献18

  • 1张文彬,刘金霞.中药抗肿瘤侵袭转移作用的研究进展[J].临床荟萃,2004,19(16):958-959. 被引量：8
  • 2朱晓光.晚期前列腺癌的中医药治疗现状[J].现代中西医结合杂志,2006,15(11):1552-1553. 被引量：11
  • 3Boikos SA, Antonarakis ES. Immunotherapy for prostate cancer enters its golden age [J]. Clin Med Insights Oncol, 2012, 6:263-273.
  • 4Kuwahara M, Tochigi T, Kawamaura S, et al.Mass screening for prostate cancer: a comparative study in Natori, Japan and Changchun, China[J]. Urology, 2003, 61(1): 137-141.
  • 5Jemal A, Siegel R, Xu J, et al.Cancer statistics, 2010[J].CA Cancer J Clin, 2010, 60(5): 277-300.
  • 6Heidenreich A, Bastian P J, Bellmunt J, et al.Guidelines on prostatecancer[J].Drukkerij Gelderland Bv, 2013, 40(2): 546-551.
  • 7Prostate Cancer Trialists Collaborative Group.Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials[J]. Lancet, 2000, 355(9214): 1491-1498.
  • 8Lage M J, Barber B L, Harrison D J, et al.The cost of treating skeletal- related events in patients with prostate cancer[J].Am J Manag Care, 2008, 14(5): 317-322.
  • 9Kingsley L A, Foumier P G J, Chirgwin J M, et al.Molecular biology of bonemetastasis[J].MolCancerTher, 2007, 6(10): 2609-2617.
  • 10Rack B, Juckstock J, Genss EM, et al.Effect of zoledronate on pe~isting isolated tumour cells in patients with early breast cancer[J].Anticancer Res, 2010, 30(5): 1807-1813.

引证文献3

二级引证文献50

华西医学
2011年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部